A pilot study: 131I-Antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost

Neuro-Oncology

Volumn 10, Issue 2, 2008, Pages 182-189

  Reardon, David A ^a   Zalutsky, Michael R ^a   Akabani, Gamal ^a   Coleman, R Edward ^a   Friedman, Allan H ^a   Herndon II, James E ^a   McLendon, Roger E ^a   Pegram, Charles N ^a   Quinn, Jennifer A ^a   Rich, Jeremy N ^a   Vredenburgh, James J ^a   Desjardins, Annick ^a   Guruangan, Sridharan ^a   Boulton, Susan ^a   Raynor, Renee H ^a   Dowell, Jeanette M ^a   Wong, Terence Z ^a   Zhao, Xiao Guang ^a   Friedman, Henry S ^a   Bigner, Darell D ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Glioblastoma multiforme; Malignant glioma; Monoclonal antibody; Radioimmunotherapy

Indexed keywords

AMINOTRANSFERASE; ANTIBIOTIC AGENT; CORTICOSTEROID; ETOPOSIDE; IRINOTECAN; LOMUSTINE; MONOCLONAL ANTIBODY; TEMOZOLOMIDE; TENASCIN MONOCLONAL ANTIBODY 81C6 I 131; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; RADIOACTIVE IODINE; TENASCIN;

ADULT; AGED; ANEMIA; ANTIBODY TITER; ARTICLE; ASTROCYTOMA; AVASCULAR NECROSIS; BLOOD TOXICITY; BRAIN BIOPSY; BRAIN INFECTION; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CAUSE OF DEATH; CENTRAL NERVOUS SYSTEM INFECTION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG TOLERABILITY; EPILEPTIC STATE; EXTERNAL BEAM RADIOTHERAPY; FEMALE; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; GLIOBLASTOMA; GLIOMA; HALF LIFE TIME; HEADACHE; HUMAN; HUMAN TISSUE; HYPERGLYCEMIA; HYPONATREMIA; HYPOTHYROIDISM; INTESTINE DIVERTICULOSIS; ISOTOPE LABELING; MALE; NEUROTOXICITY; NEUTROPENIA; ONCOLOGY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PILOT STUDY; PROGNOSIS; RADIATION DOSE; RADIOACTIVITY; RADIOIMMUNOTHERAPY; RADIOISOTOPE THERAPY; RASH; REOPERATION; SEIZURE; SEPTIC SHOCK; SIDE EFFECT; STEREOTACTIC BIOPSY; SURVIVAL TIME; THROMBOCYTOPENIA; THROMBOSIS; TOXICITY; UNITED STATES; WOUND HEALING; WOUND INFECTION; ANIMAL; BRAIN TUMOR; DRUG EFFECT; IMMUNOLOGY; INDWELLING CATHETER; INTRALESIONAL DRUG ADMINISTRATION; KAPLAN MEIER METHOD; METHODOLOGY; MIDDLE AGED; MORTALITY; MOUSE; MULTIMODALITY CANCER THERAPY;

ADULT; AGED; ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CATHETERS, INDWELLING; COMBINED MODALITY THERAPY; FEMALE; GLIOMA; HUMANS; INJECTIONS, INTRALESIONAL; IODINE RADIOISOTOPES; KAPLAN-MEIERS ESTIMATE; MALE; MICE; MIDDLE AGED; PILOT PROJECTS; RADIOIMMUNOTHERAPY; TENASCIN;

EID: 44849110617     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1215/15228517-2007-053     Document Type: Article

References (36)

1. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987-996.
2. Wong ET, Hess KR, Gleason MJ, et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol. 1999;17:2572-2578.
3. Gaspar LE, Fisher BJ, Macdonald DR, et al. Supratentorial malignant glioma: patterns of recurrence and implications for external beam local treatment. Int J Radiat Oncol Biol Phys. 1992;24:55-57.
4. Reardon DA, Akabani G, Coleman RE, et al. Salvage radioimmunother-apy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results. J Clin Oncol. 2006;24:115-122.
5. Reardon DA, Akabani G, Coleman RE, et al. Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas. J Clin Oncol. 2002;20:1389-1397.
6. Cokgor I, Akabani G, Kuan CT, et al. Phase I trial results of iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with newly diagnosed malignant gliomas. J Clin Oncol. 2000;18:3862-3872.
7. Bigner DD, Brown MT, Friedman AH, et al. Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: phase I trial results. J Clin Oncol. 1998;16:2202-2212.
8. Bigner DD, Brown M, Coleman RE, et al. Phase I studies of treatment of malignant gliomas and neoplastic meningitis with 131 I-radiolabeled monoclonal antibodies anti-tenascin 81C6 and anti-chondroitin proteoglycan sulfate Me1-14 F (ab′)2 - a preliminary report. J Neuroon-col. 1995;24:109-122.
9. Ventimiglia JB, Wikstrand CJ, Ostrowski LE, et al. Tenascin expression in human glioma cell lines and normal tissues. J Neuroimmunol. 1992;36:41-55.
10. Bourdon MA, Wikstrand CJ, Furthmayr H, Matthews TJ, Bigner DD. Human glioma-mesenchymal extracellular matrix antigen defined by monoclonal antibody. Cancer Res. 1983;43:2796-2805.
11. Bourdon MA, Matthews TJ, Pizzo SV, Bigner DD. Immunochemical and biochemical characterization of a glioma-associated extracellular matrix glycoprotein. J Cell Biochem. 1985;28:183-195.
12. Bourdon MA, Coleman RE, Blasberg RG, Groothuis DR, Bigner DD. Monoclonal antibody localization in subcutaneous and intracranial human glioma xenografts: paired-label and imaging analysis. Anti-cancer Res. 1984;4:133-140.
13. Colapinto EV, Lee YS, Humphrey PA, et al. The localisation of radiolabelled murine monoclonal antibody 81C6 and its Fab fragment in human glioma xenografts in athymic mice. Br J Neurosurg. 1988;2:179-191.
14. Lee YS, Bullard DE, Zalutsky MR, et al. Therapeutic efficacy of anti-glioma mesenchymal extracellular matrix 131I-radiolabeled murine monoclonal antibody in a human glioma xenograft model. Cancer Res. 1988;48:559-566.
15. Lee YS, Bullard DE, Wikstrand CJ, et al. Comparison of monoclonal antibody delivery to intracranial glioma xenografts by intravenous and intracarotid administration. Cancer Res. 1987;47:1941-1946.
16. Zalutsky MR, Moseley RP, Coakham HB, Coleman RE, Bigner DD. Pharmacokinetics and tumor localization of 131I-labeled anti-tenascin monoclonal antibody 81C6 in patients with gliomas and other intra-cranial malignancies. Cancer Res. 1989;49:2807-2813.
17. Akabani G, Cokgor I, Coleman RE, et al. Dosimetry and dose-response relationships in newly diagnosed patients with malignant gliomas treated with iodine-131-labeled anti-tenascin monoclonal antibody 81C6 therapy. Int J Radiat Oncol Biol Phys. 2000;46:947-958.
18. U.S. Food and Drug Administration. Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use. Rockville, MD: U.S. Department of Health and Human Services; 1997.
19. Akabani G, Reist CJ, Cokgor I, et al. Dosimetry of 131I-labeled 81C6 monoclonal antibody administered into surgically created resection cavities in patients with malignant brain tumors. J Nucl Med. 1999;40:631-638.
20. Weitzner MA, Meyers CA, Gelke CK, et al. The Functional Assessment of Cancer Therapy (FACT) scale. Development of a brain subscale and revalidation of the general version (FACT-G) in patients with primary brain tumors. Cancer. 1995;75:1151-1161.
21. Ruff RM, Allen CC. Ruff 2 & 7 Selective Attention Test Professional Manual. Odessa, TX: Psychological Resource, Inc.; 1996.
22. Benedict RHB, Schretlen D, Groniger L. Hopkins verbal learning test-revised: normative data and analysis of inter-form and test-retest reliability. Clin Neuropsychol. 1998;12:43-55.
23. Lezak MD, Howieson DB, Loring DW. Neuropsychological Assessment. New York: Oxford University Press; 2004.
24. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
25. Larson DA, Suplica JM, Chang SM, et al. Permanent iodine 125 brachytherapy in patients with progressive or recurrent glioblastoma multiforme. Neuro-Oncology 2004;6:119-126.
26. Tsao MN, Mehta MP, Whelan TJ, et al. The American Society for Therapeutic Radiology and Oncology (ASTRO) evidence-based review of the role of radiosurgery for malignant glioma. Int J Radiat Oncol Biol Phys. 2005;63:47-55.
27. Wen PY, Alexander E III, Black PM, et al. Long term results of ste-reotactic brachytherapy used in the initial treatment of patients with glioblastomas. Cancer. 1994;73:3029-3036.
28. Videtic GMM, Gaspar LE, Zamorano L, et al. Use of the RTOG recursive partitioning analysis to validate the benefit of iodine-125 implants in the primary treatment of malignant gliomas. Int J Radiat Oncol Biol Phys. 1999;45:687-692.
29. Sneed PK, Lamborn K, Larson DA, et al. Demonstration of brachyther-apy boost dose-response relationships in glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 1996;35:37-44.
30. Shrieve DC, Alexander E III, Wen PY, et al. Comparison of stereotactic radiosurgery and brachytherapy in the treatment of recurrent glio-blastoma multiforme. Neurosurgery. 1995;36:275-284.
31. Scharfen CO, Sneed PK, Wara WM, et al. High activity iodine-125 interstitial implant for gliomas. Int J Radiat Oncol Biol Phys. 1992;24:583-591.
32. Masciopinto JE, Levin AB, Mehta M, et al. Stereotactic radiosur-gery for glioblastoma: a final report of 31 patients. J Neurosurg. 1995;82:530-535.
33. Loeffler JS, Alexander E III, Wen PY, et al. Results of stereotactic brachytherapy used in the initial management of patients with glio-blastoma. J Natl Cancer Inst. 1990;82:1918-1921.
34. Laperriere NJ, Leung PMK, McKenzie S, et al. Randomized study of brachytherapy in the initial management of patients with malignant astrocytoma. Int J Radiat Oncol Biol Phys. 1998;41:1005-1011.
35. Flickinger JC, Loeffler JS, Larson DA. Stereotactic radiosurgery for intracranial malignancies. Oncology (Williston Park). 1994;8:1-86, 94, 97-98.
36. Westphal M, Hilt DC, Bortey E, et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro-Oncology 2003;5:79-88.